| Autor: |
Hasibuan AS; Division of Allergy and Clinical Immunology, Department of Internal Medicine, Faculty of Medicine, University of Indonesia/Cipto Mangunkusumo General Hospital, Jakarta 10430, Indonesia., Koesnoe S; Division of Allergy and Clinical Immunology, Department of Internal Medicine, Faculty of Medicine, University of Indonesia/Cipto Mangunkusumo General Hospital, Jakarta 10430, Indonesia., Widhani A; Division of Allergy and Clinical Immunology, Department of Internal Medicine, Faculty of Medicine, University of Indonesia/Cipto Mangunkusumo General Hospital, Jakarta 10430, Indonesia., Muhadi M; Division of Cardiology, Department of Internal Medicine, Faculty of Medicine, University of Indonesia/Cipto Mangunkusumo General Hospital, Jakarta 10430, Indonesia., Shatri H; Division of Psychosomatic and Palliative Care, Department of Internal Medicine, Faculty of Medicine, University of Indonesia/Cipto Mangunkusumo General Hospital, Jakarta 10430, Indonesia., Ginanjar E; Division of Cardiology, Department of Internal Medicine, Faculty of Medicine, University of Indonesia/Cipto Mangunkusumo General Hospital, Jakarta 10430, Indonesia., Yunihastuti E; Division of Allergy and Clinical Immunology, Department of Internal Medicine, Faculty of Medicine, University of Indonesia/Cipto Mangunkusumo General Hospital, Jakarta 10430, Indonesia., Soewondo P; Division of Endocrine System, Metabolism and Diabetes, Department of Internal Medicine, Faculty of Medicine, University of Indonesia/Cipto Mangunkusumo General Hospital, Jakarta 10430, Indonesia., Aman Nasution S; Indonesian Society of Internal Medicine, Jakarta 10430, Indonesia., Djauzi S; Adult Immunization Task Force, Indonesian Society of Internal Medicine, Jakarta 10430, Indonesia., Dina Liastuti L; Cipto Mangunkusumo General Hospital, Jakarta 10430, Indonesia., Koento T; Cipto Mangunkusumo General Hospital, Jakarta 10430, Indonesia., Sumariyono S; Cipto Mangunkusumo General Hospital, Jakarta 10430, Indonesia., Mulyantini A; Cipto Mangunkusumo General Hospital, Jakarta 10430, Indonesia. |
| Abstrakt: |
The COVID-19 pandemic has caused significant morbidity and mortality worldwide, especially among health-care workers. One of the most important preventive measures is vaccination. This study examined factors associated with the incidence rate of SARS-CoV-2 infection after mRNA-1273 booster vaccination (preceded by the CoronaVac primary vaccination) and the antibody profile of health-care workers at one of the tertiary hospitals in Indonesia. This was a combined retrospective cohort and cross-sectional study. Three hundred health-care workers who were given the mRNA-1273 booster vaccine a minimum of 5 months prior to this study were randomly selected. Participants were then interviewed about their history of COVID-19 vaccination, history of SARS-CoV-2 infection, and comorbidities. Blood samples were taken to assess IgG sRBD antibody levels. The median antibody level was found to be 659 BAU/mL (min 37 BAU/mL, max 5680 BAU/mL, QIR 822 BAU/mL) after the booster, and this was not related to age, sex, comorbidities, or adverse events following immunization (AEFI) after the booster. SARS-CoV-2 infection after the booster was correlated with higher antibody levels. In sum, 56 participants (18.6%) experienced SARS-CoV-2 infection after the mRNA-1273 booster vaccination within 5 months. Incidence per person per month was 3.2%. Age, sex, diabetes mellitus type 2, hypertension, obesity, and post-booster AEFI were not related to COVID-19 incidence after the booster. History of SARS-CoV-2 infection before the booster vaccination was significantly associated with a reduced risk of SARS-CoV-2 infection after booster vaccination, with a relative risk (RR) of 0.21 (95% CI 0.09-0.45, p < 0.001). |
